Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

The emotional toll canine cancer takes on dog owners demonstrates the need for the Canine Cancer Care Index. Only 18% of dog owners who have been through such an ordeal gave a perfect score to their overall canine cancer treatment experience.

Gallup Survey Estimates Nearly 30 Million U.S. Dog Owners Have Experienced Canine Cancer, with Many Saying it Negatively Impacted Their Own Quality of Life

New patent bolsters intellectual property protection for the company's core target indication for crofelemer Crofelemer is the subject of the company's OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy SAN FRANCISCO, CA / ACCESSWIRE / August 9, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the United States Patent and Trademark Office on July 19, 2022 issued a new U.S. patent to Napo Pharmaceuticals (Napo), the company's wholly owned subsidiary, for methods for treating diarrhea, as well as the pain, abdominal discomfort and other symptoms associated with diarrhea, in patients with an inhibitor of chloride-ion transport such as Napo's crofelemer drug product. "We are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core target indication of cancer therapy-related diarrhea (CTD)," said Lisa Conte, Jaguar's founder, president, and CEO.

Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea

OPKO Health

Oatly

Are these market trends part of your penny stocks trading strategy? The post Penny Stocks, Market Trends in July 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks, Market Trends in July 2022

Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee SAN FRANCISCO, CA / ACCESSWIRE / July 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that it has appointed Anula Jayasuriya, M.D., Ph.D., M.B.A.

Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions

Color Star Technology

Inpixon

Here's what you need to know about buying penny stocks on June 29th The post What to Know About Buying Penny Stocks on June 30th  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 30th

License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months Service agreement of up to $5.0 million payable in unregistered Jaguar stock to SynWorld to support approval of crofelemer in China, providing Jaguar Health with up to 80% of profits SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the company has entered an exclusive license and services agreement with Ontario, Canada-based SynWorld Technologies Corporation (SynWorld) for the treatment of diarrhea in dogs in the China market with Jaguar's Canalevia® (crofelemer delayed-release tablets) prescription drug product. "We are very excited about the possibility of making Canalevia available in China as part of the license we have provided to SynWorld for crofelemer for treatment of diarrhea in dogs in this territory," said Lisa Conte, Jaguar's founder, president, and CEO.

Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China

Chimerix

RedHill Biopharma

Can these penny stocks make gains this coming week? The post Hot Penny Stocks to Buy Right Now?

Hot Penny Stocks to Buy Right Now? Check These 3 Out

SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome (SBS) at the Elite Ped-GI Congress, which took place May 19-21, 2022 in Abu Dhabi in the United Arab Emirates, is available online. The presentation, titled Short Bowel Syndrome: New Hope in the Horizon, can be accessed by clicking here.

Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi

Canalevia®-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / June 21, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company is exhibiting at the American College of Veterinary Internal Medicine (ACVIM) Forum, which takes place June 23 - 25, 2022 in Austin, TX, as part of ongoing commercial launch activities for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company's FDA conditionally approved prescription drug product for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is now available from multiple leading veterinary distributors in the U.S. Jaguar Animal Health is sponsoring the two below events at the ACVIM Forum: Oncology Specialty Symposium Lunch & Business Meeting: Wednesday, June 22, 2022, 12:00 - 2:00 CT, Hilton Austin Grand Ballroom G Scientific session: Tolerability and Pharmacokinetic Parameters for Anticancer Agents in Dogs: Friday, June 24, 2022, 11:00 - 11:30 CT, Austin Convention Center 16AB Jaguar Animal Health is showcasing Canalevia-CA1 at exhibit booth number 521 at the ACVIM Forum.

Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1

Diarrhea is also a prevalent side effect in dogs undergoing cancer treatment; managing diarrhea can be important to maintain successful cancer treatment in both humans and dogs SAN FRANCISCO, CA / ACCESSWIRE / June 13, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an article by Dr. Kathleen Kiernan Harnden titled Alleviating Targeted Therapy Side Effects: Essential for Patient QOL and Best Outcomes was published June 8, 2022 in Onco'Zine. Highlights from the article: As many as 50% to 100% of cancer patients experience diarrhea, depending on their treatment regimen.

Jaguar Health Announces Publication of Onco'Zine Article Underscoring the Importance of Controlling Diarrhea in Cancer Patients

All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2022 Annual Meeting of Stockholders held on June 10, 2022. Four proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting.

Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders

Jaguar seeking partnering meetings at BIO 2022 related to the company's novel plant-based FDA-approved anti-secretory agent for cancer therapy-related diarrhea (CTD) and inflammatory bowel disease (IBD) and its large proprietary library of medicinal plants, including plants with novel psychedelic and other psychoactive effects SAN FRANCISCO, CA / ACCESSWIRE / June 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Karen Brunke, PhD, the company's Executive Vice President of Corporate and Business Development, will be attending BIO 2022, taking place at the San Diego Convention Center from June 13 - 16, 2022. Dr. Brunke will be participating in one-on-one meetings throughout the conference.

Jaguar Health to Participate in BIO International Convention (BIO 2022)

Drug Discovery Collaboration Will Leverage the Botanical Drug Development Expertise of Both Companies SAN FRANCISCO, CA / ACCESSWIRE / June 9, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) and Filament Health Corp. (NEO:FH) today announced that the companies have signed a letter of intent to enter a collaboration agreement to develop botanical prescription drugs for specific psychoactive target indications in the United States. The goal of the collaboration is to extend the botanical drug development skillsets of both companies in order to develop pharmaceutical-grade, standardized drug candidates and partner with a potential future licensee regarding the development and commercialization of these novel plant-based drugs for indications such as attention-deficit/hyperactivity disorder (ADHD) and social anxiety disorder.

Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications

Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2022 / Jaguar Health (NASDAQ:JAGX) today announced that Napo Therapeutics, the Italian corporation established by the company in Italy in 2021 that focuses on expanding crofelemer access in Europe, has submitted an Orphan Drug Designation (ODD) application for crofelemer for a rare congenital diarrheal disorder (CDD) condition called microvillus inclusion disease (MVID) to the European Medicines Agency (EMA). The submission is the first step of the process; the review by the EMA's Committee for Orphan Medicinal Products (COMP) will start after the validation of the submission.

Jaguar Health Announces Napo Therapeutics' Submission of Orphan Drug Designation Application to the European Medicines Agency for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Condition

Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the presentation of an investigator-initiated in vitro study evaluating the efficacy of crofelemer, the company's plant-based prescription drug, as a potential anti-diarrheal to mitigate the consequences of microvillus inclusion disease (MVID), a severe congenital diarrheal disorder (CDD), at Digestive Disease Week ® (DDW 2022), which took place May 21-24, 2022 in San Diego, CA. "Microvillus inclusion disease (MVID) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea," said Pravin Chaturvedi, PhD, Jaguar Health's Chief Scientific Officer and Chair of the company's Scientific Advisory Board.

Jaguar Health Announces Presentation of an Investigator-initiated Evaluation of Crofelemer for a Severe Congenital Diarrheal Disorder at 2022 Digestive Disease Week

Catalyst Biosciences

Cybin

Kala Pharmaceuticals

Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 To Watch Under $1

"Canine Cancer: Take C.H.A.R.G.E." (Canine Health And ReGistry Exchange) Based on Nationwide Gallup Poll of Pet Owners and Initial Assessment of More Than 35,000 Canine Medical Records Initial Data from Gallup Poll of More Than 3,500 Dog Owners Suggest Nearly Five-Fold Greater Incidence of Canine Cancer Than Human Cancer; More Than 80 Percent of Respondents Believe a Registry is Needed to Help Dogs with Cancer Take C.H.A.R.G.E.

Jaguar Health Announces Launch of the First U.S. Canine Cancer Registry and Canine Cancer Care Index

Click here to RSVP for this in-person, outdoor event Human and doggy swag will be available*, and the event will feature presentations by well-known veterinary cancer specialists, including Dr. Sue Cancer Vet, and performances by Broadway stars This is a special event for ALL interested parties - dog owners, veterinarians, veterinary oncology specialists, investors, the media, and anyone who is concerned about addressing and managing cancer in our four-legged best friends SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) is hosting a special media event and performance in New York City on Monday, May 23rd, 2022 from 12:30 to 2:30 PM Eastern to celebrate the launch of the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) initiative - the first-ever U.S. Canine Cancer Registry and Cancer Care index - because protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location.

Media Advisory: Jaguar Health Canine Cancer: Take C.H.A.R.G.E. Launch Event in NYC on Monday, May 23rd!

SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that TAG Investment Bankers Ltd. ("TAG") issued an analyst report today on the company.

TAG Investment Bankers Ltd. Issues Analyst Report on Jaguar Health

This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the Day To Determine if Mytesi® Is Medically Appropriate for Them SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's telehealth program went live on May 6, 2022 for Mytesi (crofelemer), Jaguar's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). "Telehealth facilitates faster and more expansive patient access to much needed medical care.

Jaguar Health Announces Launch of Mytesi Telehealth Program

Jaguar Health, Inc. (NASDAQ:JAGX ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Conte – Founder, President and Chief Executive Officer Carol Lizak – Chief Financial Officer Ian H. Wendt – Chief Commercial Officer Peter Hodge – Senior Director of Investor Relations, Business Development and Special Events Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that the -- that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q1 2022 Results - Earnings Call Transcript

Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter of 2021 Core initiatives: OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) adding international sites, targeting completion of enrollment 1H 2023 Targeted completion in 2022 & 2023 of investigator-initiated proof-of-concept studies of crofelemer for short bowel syndrome and congenital diarrheal disorders, supporting the potential for expanded patient access through programs in Europe in 2023 Ongoing launch of Canalevia®-CA1, which is now commercially available for treatment of chemotherapy-induced diarrhea (CID) in dogs REMINDER: Jaguar to host investor webcast Tuesday, May 10th at 8:30 a.m. Eastern regarding first quarter 2022 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided company updates and reported consolidated first quarter 2022 financial results.

Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials

Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Tuesday, May 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.

UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Click here to register for webcast Company plans to file its Earnings Report on May 10, 2022 on Form 10-Q for the quarter ended March 31, 2022 SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host an investor webcast on Tuesday, March 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.

Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Canalevia® Would Be the First and Only Treatment for EID in Dogs To Receive Any Type of Approval From FDA SAN FRANCISCO, CA / ACCESSWIRE / May 3, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has completed filing of the final regulatory section with the U.S. Food and Drug Administration's (FDA) Center for Veterinary Medicine (CVM) to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia (crofelemer delayed-release tablets) to treat exercise-induced diarrhea (EID) in dogs. In December of 2021, Jaguar Animal Health received conditional approval from the FDA for Canalevia®-CA1 for chemotherapy-induced diarrhea (CID) in dogs.

Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs

News for Jaguar Health Stock (JAGX)